Evidence map›Paper›PMID 41526551›Full record

ArticleNature immunology2026

PARP inhibition generates enhanced CD8

Wael Traboulsi, Pankaj Gaur, Subhadip Kundu, Zainab Ramlaoui, Christopher Priestley-Milianta, Aishwariya Iyengar, Nour Shobaki, Dareen Sarhan, Min-Jung Lee, Jung-Min Lee and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Wael TraboulsiCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Pankaj GaurCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.ORCID http://orcid.org/0000-0002-9718-3565
Subhadip KunduCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Zainab RamlaouiCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Christopher Priestley-MiliantaCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.ORCID http://orcid.org/0000-0002-5030-3750
Aishwariya IyengarCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Nour ShobakiCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.ORCID http://orcid.org/0000-0001-9073-0987
Dareen SarhanCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Min-Jung LeeDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jung-Min LeeWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
George N PavlakisVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mikayel MkrtichyanCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.
Viia E Valge-ArcherAstraZeneca Oncology R&D, Cambridge, UK.
Simon T BarryAstraZeneca Oncology R&D, Cambridge, UK.ORCID http://orcid.org/0000-0002-8511-0588
Vivek VermaCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.ORCID http://orcid.org/0000-0001-8129-4140
Seema GuptaCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.ORCID http://orcid.org/0000-0003-0106-595X
Samir N KhleifCenter for Advanced Immunotherapy Research & The Loop Immuno-Oncology Research Lab, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA. snk48@georgetown.edu.ORCID http://orcid.org/0000-0003-2707-5224

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD8

Indexed as

CD8-Positive T-LymphocytesImmunologic MemoryMemory T CellsPoly(ADP-ribose) Polymerase InhibitorsAnimalsCell Line, TumorFemaleForkhead Box Protein O1HumansImmunotherapy, AdoptiveMetabolic ReprogrammingMiceMice, Inbred C57BLSirtuin 1Transcription, GeneticForkhead Box Protein O1Foxo1 protein, mousePoly(ADP-ribose) Polymerase InhibitorsSirt1 protein, mouseSirtuin 1

Identifiers

PMID41526551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.